Results From the Phase III AUGMENT Trial in Recurrent Indolent Lymphomas
December 28th 2018John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.
Watch
Findings for the Combination of Anti-TIM-3 and Anti-PD-1 in Melanoma and Lung Cancer
December 27th 2018Diwakar Davar, MBBS, MSc, discusses how data from the phase I trial of TSR-022, an anti-TIM-3 monoclonal antibody, and TSR-042, an anti-PD-1 agent, impact the treatment of patients with both melanoma and lung cancer.
Watch
Overview of R2 Regimen for Relapsed Follicular Lymphoma
December 27th 2018Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R<sup>2</sup> regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br />
Watch
Advice To Community Oncologists Treating Patients With CRC
December 20th 2018Al B. Benson III, MD, FACP, FASCO, professor of medicine at Northwestern University, shares advice to community oncologists treating patients with colorectal cancer. He emphasizes looking carefully at different patient characteristics before making treatment decisions.
Watch
An Overview of the Ongoing SIERRA Trial in Relapsed/Refractory AML
December 19th 2018Rajneesh Nath, MD, director, stem cell transplant and acute leukemia program, Banner MD Anderson Cancer Center, discusses the ongoing phase III SIERRA trial, which is evaluating targeted conditioning of Iomab-B prior to allogeneic hematopoietic cell transplantation versus conventional care in patients with relapsed/refractory acute myeloid leukemia (AML).<br />
Watch